Scotch Plains, NJ, United States of America

Unmesh G Shah

This inventor holds 16 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Merck Canada Inc.. Active years: 2005-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Unmesh G Shah. Retrieved from https://idiyas.com/inventor/unmesh-g-shah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 2)

% Patents Active = 87.5

CIPO Patents = 3

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 58(Granted Patents)

Location History:

Roselle Park, NJ (US) (2005)
Scotch Plains, NJ (US) (2005 - 2010)
Green Brook, NJ (US) (2008 - 2015)
Watchung, NJ (US) (2016)
Neshanic Station, NJ (US) (2015 - 2021)

Company Filing History:

10 out of 2,405

Merck Sharp + Dohme Corp.

Mochida Pharmaceutical Co., Ltd.

where one patent can have more than one assignee

Years Active: 2005-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11161819 - Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists (2021-11-02),

2. 9708270 - Substituted spiropiperidinyl compounds useful as GPR120 agonists (2017-07-18),

3. 9328138 - HCV NS3 protease inhibitors (2016-05-03),

4. 8987242 - Morpholinone compounds as factor IXA inhibitors (2015-03-24),

5. 8987195 - HCV NS3 protease inhibitors (2015-03-24),

6. 8604195 - Substituted bicyclic piperidinyl- and piperazinyl-sulfonamides useful to inhibit 11β-hydroxysteroid dehydrogenase type-1 (2013-12-10),

7. 8580807 - Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders (2013-11-12),

8. 8466149 - 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I (2013-06-18),

9. 8389532 - 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-E]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine (2013-03-05),

10. 8318751 - Pyrimidinone derivatives and methods of use thereof (2012-11-27),

11. 7709492 - [object Object] (2010-05-04),

12. 7572802 - 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine (2009-08-11),

13. 7465740 - 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists (2008-12-16),

14. 7368449 - [object Object] (2008-05-06),

15. 6916811 - Adenosine A2a receptor antagonists (2005-07-12),

Title: Unmesh G Shah: Innovator in Pharmaceutical Compounds

Introduction

Unmesh G Shah is a prominent inventor based in Scotch Plains, NJ (US), known for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has made remarkable advancements in the development of compounds that target various health conditions.

Latest Patents

Among his latest inventions are the substituted tetrahydroisoquinoline compounds, which are recognized for their utility as GPR120 agonists. These compounds are designed to treat or prevent diabetes, hyperlipidemia, obesity, NASH, and inflammation-related disorders. The invention includes pharmaceutical compositions and methods of treatment that leverage these compounds. Another notable patent involves substituted spiropiperidinyl compounds, also serving as GPR120 agonists, aimed at addressing similar health issues. These innovations highlight his commitment to improving health outcomes through targeted pharmaceutical solutions.

Career Highlights

Unmesh G Shah has had a distinguished career, working with leading companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Schering Corporation, where he has contributed to various research and development projects. His work has been instrumental in advancing the understanding and treatment of complex health conditions.

Collaborations

Throughout his career, Unmesh has collaborated with notable professionals in the field, including Samuel Chackalamannil and Craig D Boyle. These collaborations have further enriched his research and innovation efforts.

Conclusion

Unmesh G Shah's contributions to pharmaceutical innovations demonstrate his expertise and dedication to improving health through science. His patents reflect a deep understanding of complex medical challenges and a commitment to finding effective solutions.

Profile summary based on public USPTO records.